Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D C Smith

Showing results (281-290 of 545) with videos related to

Pageof 55
Sort By:
Radiology|February 1, 1990
Thrombin generation in nonclottable mixtures of blood and nonionic contrast agentsP M Kopko, D C Smith, B S Bull
Cancer Research|February 1, 1973
The carcinogenic potential of aflatoxin or its metabolites in rats from dams fed aflatoxin pre- and postpartumH C Grice, C A Moodie, D C Smith
Journal of the Canadian Dental Association|September 1, 1972
Cementation of dental implants: rationale and preliminary observationsG A Zarb, A H Melcher, D C Smith
American Journal of Clinical Oncology|June 1, 1997
Megestrol acetate in the treatment of hormone refractory prostate cancerJ L Osborn, D C Smith, D L Trump
University of Toronto Dental Journal|January 1, 1989
Nickel hypersensitivity reactions in orthodontic patients. A literature reviewA L Greppi, D C Smith, D G Woodside
Community Dentistry and Oral Epidemiology|September 1, 1977
Study of a fissure sealant in mentally retarded Canadian childrenB A Richardson, D C Smith, J A Hargreaves
Radiology|August 1, 1989
Differing mechanisms of clotting inhibition by ionic and nonionic contrast agentsJ J Ing, D C Smith, B S Bull
The Journal of Trauma|April 1, 1982
Embolotherapy of a ruptured internal mammary artery secondary to blunt chest traumaD C Smith, M O Senac, L L Bailey
Drugs|March 11, 2000
Oral chemotherapy in the treatment of hormone-refractory prostate cancerK J Pienta, J M Kamradt, D C Smith
Cancer|June 8, 2001
Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma: a phase II trial of oral estramustine and oral etoposideH G Munshi, K J Pienta, D C Smith
Pageof 55

Showing results (281-290 of 545) with videos related to

Sort By:
Pageof 55
Radiology|February 1, 1990
Thrombin generation in nonclottable mixtures of blood and nonionic contrast agentsP M Kopko, D C Smith, B S Bull
Cancer Research|February 1, 1973
The carcinogenic potential of aflatoxin or its metabolites in rats from dams fed aflatoxin pre- and postpartumH C Grice, C A Moodie, D C Smith
Journal of the Canadian Dental Association|September 1, 1972
Cementation of dental implants: rationale and preliminary observationsG A Zarb, A H Melcher, D C Smith
American Journal of Clinical Oncology|June 1, 1997
Megestrol acetate in the treatment of hormone refractory prostate cancerJ L Osborn, D C Smith, D L Trump
University of Toronto Dental Journal|January 1, 1989
Nickel hypersensitivity reactions in orthodontic patients. A literature reviewA L Greppi, D C Smith, D G Woodside
Community Dentistry and Oral Epidemiology|September 1, 1977
Study of a fissure sealant in mentally retarded Canadian childrenB A Richardson, D C Smith, J A Hargreaves
Radiology|August 1, 1989
Differing mechanisms of clotting inhibition by ionic and nonionic contrast agentsJ J Ing, D C Smith, B S Bull
The Journal of Trauma|April 1, 1982
Embolotherapy of a ruptured internal mammary artery secondary to blunt chest traumaD C Smith, M O Senac, L L Bailey
Drugs|March 11, 2000
Oral chemotherapy in the treatment of hormone-refractory prostate cancerK J Pienta, J M Kamradt, D C Smith
Cancer|June 8, 2001
Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma: a phase II trial of oral estramustine and oral etoposideH G Munshi, K J Pienta, D C Smith
Pageof 55